Modality
Nanobody
MOA
PD-1i
Target
AuroraA
Pathway
Neuroinflam
NSCLC
Development Pipeline
Preclinical
~Jun 2017
→ ~Sep 2018
Phase 1
~Dec 2018
→ ~Mar 2020
Phase 2
Jun 2020
→ Mar 2030
Phase 2Current
NCT06066182
2,925 pts·NSCLC
2025-11→2026-05·Recruiting
NCT05607246
728 pts·NSCLC
2020-06→2030-03·Terminated
3,653 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-07-258mo agoEMA Filing· NSCLC
2026-05-011mo awayPh3 Readout· NSCLC
2030-03-053.9y awayPh3 Readout· NSCLC
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P2/3
Termina…
P2/3
Recruit…
Catalysts
EMA Filing
2025-07-25 · 8mo ago
NSCLC
Ph3 Readout
2026-05-01 · 1mo away
NSCLC
Ph3 Readout
2030-03-05 · 3.9y away
NSCLC
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06066182 | Phase 2/3 | NSCLC | Recruiting | 2925 | MRD |
| NCT05607246 | Phase 2/3 | NSCLC | Terminated | 728 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Motarapivir | GSK | Preclinical | AuroraA | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| Nirabrutinib | BioNTech | Phase 2/3 | CDK2 | |
| ARG-6988 | Argenx | Preclinical | AuroraA | |
| Cevinaritide | Genmab | Phase 2/3 | DLL3 | |
| Semamavacamten | Ideaya Bio | Phase 1/2 | AuroraA | |
| Cevinaritide | Praxis Precision | Phase 3 | AuroraA | |
| SND-4562 | Syndax | NDA/BLA | AuroraA |